CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

基本信息

批准号：
3555902
负责人：
RICHARD T SILVER
金额：
$ 15.07万
依托单位：
WEILL MEDICAL COLL OF CORNELL UNIV
依托单位国家：
美国
项目类别：
财政年份：
1979
资助国家：
美国
起止时间：
1979-04-01 至 1988-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/3555902
关键词：
6 thioguanine 6 thiopurine Hodgkin's disease anticoagulants asparaginase blood proteins cancer information system cancer rehabilitation mental health service carmustine central nervous system neoplasms cooperative study cyclophosphamide cytosine arabinoside dacarbazine data collection methodology /evaluation daunorubicin drug metabolism enzyme therapy fluorouracil human subject human therapy evaluation lymphocytic leukemia lymphoma melphalan methotrexate multiple myeloma myelogenous leukemia neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy neoplasm /cancer radiation therapy neoplasm /cancer remission /regression neoplasm /cancer surgery nephroblastoma neuroblastoma oncology nursing pediatric neoplasm /cancer prednisone radiation therapy dosage reticuloendotheliosis vincristine

项目摘要

This is an application for continuing research in clinical cancer as a member of CALGB. The New York Hospital-Cornell Medical Center together with its associated institutions, North Shore University Hospital and the Firestone Radiation Center at Memorial Hospital, remains a major contributor to the scientific, clinical and administrative activities of CALGB. These are reflected in our participation in the scientific affairs and programs of CALGB. Leadership activities are reflected in our administrative and scientific contributions to CALGB, and in our pilot and phase II programs and in our publications. Our aims are to participate in a cooperative approach in the design and conduct of therapeutic trials in cancer. In this context, we will (1) determine the effect, extent and duration of remission and other responses to treatment of the diseases currently of concern to CALGB, (2) study the natural history and some of the biologic agents of the diseases investigated by CALGB as modified by various experimental therapeutic regimens, (3) promote the best possible treatment of these disorders, (4) participate in pilot phase II and multidisciplinary trials of CALGB, (5) continue a high level of patient accrual and continue to improve data collection, (6) continue our vigorous participation in Group activities as it pertains to Group science and Group administration with particular reference to change in the Group's orientation and resources in the last two years.

这是作为临床癌症继续研究的应用 Calgb的成员。纽约医院核心医疗中心一起及其相关机构，北岸大学医院和纪念医院的Firestone辐射中心仍然是主要的为科学，临床和行政活动的贡献者校准。这些反映在我们参与科学事务和CALBB的程序。领导活动反映在我们的对Calgb以及我们的飞行员的行政和科学贡献第二阶段计划和我们的出版物。我们的目的是参与设计合作的方法，癌症治疗试验的进行。在这种情况下，我们将（1）确定缓解的效果，程度和持续时间和其他反应为了治疗当前关注的Calb的疾病，（2）研究自然史和某些疾病的生物学毒剂由CALB研究通过各种实验性治疗进行了修饰方案，（3）促进这些疾病的最佳治疗方法，（4）参加CALB的II阶段和多学科试验，（5）继续高水平的患者应计并继续改善数据收集，（6）继续我们的团体活动，以它与特定的小组科学和小组管理有关参考最后一个小组的方向和资源的变化两年。